Metformin, B12, and enhanced breast cancer response to chemotherapy

Journal of Clinical Oncology

Volumn 28, Issue 2, 2010, Pages

  Garcia, April ^a   Tisman, Glenn ^a  

^a Whittier Cancer Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; METFORMIN; METHOTREXATE; PACLITAXEL; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CELL PROLIFERATION; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; FOLIC ACID DEFICIENCY; HUMAN; LETTER; LEUKEMIA; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOADJUVANT THERAPY; VITAMIN B 12 DEFICIENCY;

EID: 74949086191     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.7857     Document Type: Letter

References (17)

1. Jiralerspong S, Giordano SH, Palla SL, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302
2. Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in patients. BMJ 330:1304-1305, 2005
3. Li D, Yeung S-CJ, Hassan MM, et al: Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482-488, 2009
4. Zakikhani M, Dowling R, Fantus IG, et al: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273, 2006
5. Dowling RJ, Zakikhani M, Fantus IG, et al: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812, 2007
6. Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576-3586, 2008
7. Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tymor cell growth. Cancer Res 67:6745-6752, 2007
8. Huang X, Wullschleger S, Shpiro N, et al: Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412:211-211, 2008
9. Anisimov VN, Berstein LM, Egormin PA, et al: Effect of metformin on the life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40:1037-1044, 2006
10. 12 deficiency in patients receiving metformin. Arch Intern Med 166:1975-1979, 2006
11. Plant AS, Tisman G: Frequency of combined deficiencies of vitamin D and holotranscobalamin in cancer patients. Nutr Cancer 56:143-148, 2006
12. Tisman G, Kutik S, Khan Y: Chemotherapy-induced suppression of serum holotranscobalamin. J Clin Oncol 27, 2009 (suppl; abstr e20639)
13. Goldhirsch A, Gelber RD, Tattersall MN, et al: Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer. Lancet 2:151, 1987
14. Eastwood DW, Green CD, Lambdin MA, et al: Effect of nitrous oxide on the white-cell count in leukemia. N Engl J Med 268:297-299, 1963
15. Lassen HCA, Henriksen E, Neukirch F, et al: Treatment of tetanus, severe bone marrow depression after prolonged nitrous oxide anaesthesia. Lancet 1:527-530, 1956
16. Vu T, Amin J, Ramos M, et al: New assay for the rapid determination of plasma holotranscobalamin II levels: Preliminary evaluation in cancer patients. Am J Hematol 42:202-211, 1993
17. 12 content and concentrations of plasma holotranscobalamin II. Am J Hematol 43:226-229, 1993